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Abstract
Acute graft-versus-host disease (aGvHD) contributes to about 50% of transplant-related mortality (non-relapse mortality)
after allogeneic hematopoietic stem cell transplantation (HSCT). Here the predictive value of a urinary proteomic profile
(aGvHD_MS17) was tested together with preemptive prednisolone therapy. Two-hundred and fifty-nine of 267 patients were
eligible for analysis. Ninety-two patients were randomized upon aGvHD_MS17 classification factor above 0.1 to receive
either prednisolone (2–2.5 mg/kg, N= 44) or placebo (N= 47; N= 1 randomization failure) for 5 days followed by tapering.
The remaining 167 patients formed the observation group. The primary endpoint of the randomized trial was incidence of
aGvHD grade II between randomization and day +100 post HSCT. Analysis of the short-term preemptive prednisolone
therapy in the randomized patients showed no significant difference in incidence or severity of acute GvHD (HR: 1.69, 95%
CI: 0.66–4.32, P= 0.27). Prednisolone as preemptive treatment did not lead to an increase in relapse (20.2% in the placebo
and 14.0% in the prednisolone group (P= 0.46)). The frequency of adverse events was slightly higher in the placebo group
(64.4% versus 50%, respectively). Taken together, the results of the Pre-GvHD trial demonstrated the feasibility and safety
of preemptive prednisolone treatment in the randomized patients.
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Acute graft-versus-host disease (aGvHD) is a severe
complication of allogeneic hematopoietic stem cell
transplantation (HSCT) and is diagnosed by clinical fea-
tures, such as skin rash, diarrhea, or elevation of liver
enzymes followed by biopsies and histopathological
examination if appropriate [1]. Between 30 and 80% of
patients develop aGvHD, depending on primary disease,
patient age, conditioning regimen, and GvHD prophylaxis
[2–4]. Initial standard therapy for aGvHD is prednisolone
at a dose of 2–2.5 mg/kg body weight per day, resulting in
a response rate of about 70% for patients with aGvHD
grades I–II [4–6].
Proteome analysis of urine using capillary electro-
phoresis coupled online to mass spectrometry (CE–MS)
to define differentially excreted urinary peptides is a
broadly applicable and powerful diagnostic tool in a
variety of diseases [7–10]. The proteomic classifier
“aGvHD_MS17” was based on 17 differentially excreted
peptides identified by CE–MS analysis in the urine of
patients after allogeneic HSCT. Upon application of
support vector machine (SVM)-based analyses tools, the
dimensionless classification factor (CF) for
aGvHD_MS17 was calculated [11]. Receiver-operated
characteristic curves were used to determine that a CF
above 0.1 could be used to separate patients with pending
aGvHD grades II–IV from those who never developed
aGvHD or had aGvHD grade I up to 21 days prior to
clinical manifestation of aGvHD [11–13]. The
aGvHD_MS17 classifier has been tested on more than
700 patients transplanted at four different transplant
centers. Apart from the aGvHD_MS17 profile, others
have described the use of ELISA to detect plasma bio-
markers, to predict aGvHD outcome and non-relapse
mortality (NRM) [14–16]. Bacigalupo et al. [17] pub-
lished the first preemptive treatment trial for aGvHD,
using ATG in all patients stratified into three risk groups
and resulting in a reduction of acute and chronic GvHD
and better overall survival (OS) in the high-risk sub-
group. The same group studied the influence of steroid
treatment in patients with aGvHD grade I randomized to
receive 1 mg prednisolone or placebo to prevent severe
GvHD [18]. Based on our previous studies, we initiated a
German multicenter trial in 2008, to evaluate the effect of
preemptive prednisolone treatment of imminent aGvHD
grades II–IV upon aGvHD_MS17 CF positivity. The
trial was an investigator initiated, prospective, multi-
center, placebo controlled, double-blind clinical trial,
registered under www.isrctn.com: ISRCTN03911524




The “Pre-emptive therapy of aGvHD according to specific
proteomic patterns after allogeneic hematopoietic stem cell
transplantation (Pre-GvHD) trial” was an investigator
initiated, prospective multicenter, double-blind, placebo
controlled, randomized phase II/III trial conducted in 11
German centers. The trial was designed and overseen by the
authors. The trial protocol was approved by the leading
ethics committee of Hannover Medical School (MHH),
those of the contributing sites and the federal regulatory
agency (BfArM). The trial was performed in accordance
with the principles of the Declaration of Helsinki.
Patients
Adult patients (from 18 years on) were included after
informed consent. Inclusion was on day +3 (range: 2–5)
after the first allogeneic HSCT. Detailed inclusion and
exclusion criteria are provided in Supplementary material.
The first patient entered the trial on December 14, 2009.
Eight patients were excluded from analysis, since no urine
samples were collected and analyzed, due to intensive care
treatment, dialysis or death prior day +7. Clinical and
demographic data for all eligible patients are summarized in
Table 1. Urine was collected at regular predefined intervals
up to 80 days post HSCT and analyzed centrally. Ninety-
two patients were randomized upon aGvHD_MS17 CF
positivity to receive either prednisolone (2–2.5 mg/kg, N=
44) or placebo (N= 48) for 5 days followed by a taper of
19 days in the absence of aGvHD. One patient of the pla-
cebo group was randomized by mistake despite only
negative samples in the aGvHD_MS17 test. The remaining
167 patients formed the observation group. Clinically
manifest aGvHD was graded according to the modified
Glucksberg criteria [19] and verified by biopsies [20] where
appropriate. Visits were made weekly until day +35 and on
days +50, +80 (all ±3 days), +100, and +130 (±10 days)
for clinical evaluation and development of aGvHD. The
follow-up was 1 year after HSCT. Figure 1 shows the trial
flow chart and the disposition of patients (Supplementary
Table 1).
Urine sample collection
Samples were collected from all patients enrolled weekly
between days +7 and +35, on days +50 and +80 (all:
±3 days) after HSCT, frozen at −20 °C and shipped to the
central laboratory (Mosaiques, Hannover, Germany) for
further analysis. The protocol required that the time between
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Age 58 (19–73) 55 (21–70) 52 (19–74)
Gender
Male 27 (56) 29 (66) 109 (66)
Female 21 (44) 15 (34) 58 (34)
Primary disease
Acute (AML, ALL, sAML) 25 (52) 24 (55) 92 (55)
Chronic (MDS, MPS, CML, CLL) 12 (25) 10 (23) 42 (25)
Lymphoma (NHL, HD,MM) 10 (21) 9 (20) 31 (19)
Nonmalignant (AA, PNH) 1 (2) 1 (2) 2 (1)
Status primary disease
CR 1/CP1 17 (35) 21 (48) 82 (49)
CR 2 or higher 5 (10) 5 (11) 20 (12)
No CR (untreated, relapse,
refractory)
25 (52) 17 (39) 58 (35)
Vo status 1(2) 1 (2) 7 (4)
Conditioning
Myeloablative (MAC) 9 (19) 13 (29.5) 40 (24)
Reduced intensity
conditioning (RIC)
39 (81) 31 (70.5) 127 (76)
Graft
PBSC 43 (90) 38 (86) 155 (93)
BM 5 (10) 6 (14) 11 (6.5)
Other – – 1 (0.5)
Immunosuppressive antibodies
None 12 (25) 10 (23) 51 (31)
ATG Fresenius 29 (60) 30 (68) 107 (64)
Thymoglobulin 2 (4) 1 (2) 4 (2)
Campath 3 (6) 3 (7) 6 (4)
GvHD prophylaxis
CSA/MTX 18 (37) 14 (32) 73 (44)
CSA/MMF 21(44) 25 (57) 73 (44)
Other 9 (19) 5 (11) 21 (12)
Donor
Related 9 (19) 13 (30) 39 (23)
Unrelated 39 (81) 31 (70) 128 (77)
HLA match
Matched 43 (90) 36 (82) 146 (87)
Mismatched 5 (10) 8 (18) 21 (13)
Gender (R/D)
Mismatched (male/female) 6 (12.5) 9 (20.4) 25 (15)
RIC protocols (N= 203) consisted of fludarabine (Flu), amsacrine, AraC, and TBI or busilvex (FLAMSA [25]; N= 31/203; 15%);
BNCU–Flu–melphalane (BFM; N= 27/203; 14%), Flu–Bu (N= 34/203; 17%); Flu–Mel (N= 34/203; 17%); Flu–treosulfane (Flu–Treo;
N= 16/203; 8%); total body irradiation (TBI)–Flu (N= 16; 8%); and other (N= 42; 21%).
Acute: AML acute myeloid leukemia, ALL acute lymphatic leukemia, sAML secondary AML; chronic: MDS/MPS myelodysplastic/proliferative
syndrome, CML chronic myeloid leukemia, CLL chronic lymphatic leukemia; lymphoma: NHL non-Hodgkin lymphoma, HD Hodgkin disease,
MM multiple myeloma; nonmalignant: SAA severe or very severe aplastic anemia, CR/CP complete remission/chronic phase; no CR untreated,
relapse, refractory, MAC myeloablative conditioning, RIC reduced intensity conditioning, PBSC peripheral blood stem cells, BM bone marrow, CB
cord blood, ATG anti-thymocyte globulin, CSA cyclosporine A, MTX methotrexate, MMF mycophenolate motefil; other: MMF, tacrolimus
(FK506), or different combinations of immunosuppressants.
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sample arrival at Mosaiques and the transmission of the
aGvHD_MS17 CF score for randomization had to be within
72 h. Sample preparation and CE–MS analyses were
described previously and summarized in Supplementary
material [21].
Blinding and randomization procedures
All patients included in the screening process received a
consecutive patient number at their study site. The patient
identifier was the combination of the study site number and
the patient number. For patients not eligible for the trial,
only demographic data and inclusion/exclusion criteria were
recorded. Two independent teams at each study site ensured
double-blinding. Team A (clinical ward team) received only
blinded medication and did not know the treatment code.
Team B (pharmacy) knew the treatment code prepared by
the independent trial statistician and prepared the
medication accordingly. Randomization lists were prepared
by the statistician at Prometris (Mannheim, Germany) who
was not involved in other tasks of the trial. Randomization
envelopes containing the treatment code were deposited at
each study site, accessible only for team B. Additionally,
sealed emergency envelopes containing the randomization
number and the treatment group was prepared for each
patient to be opened in case of signs of aGvHD grades II or
higher or another medical emergency.
Primary and secondary endpoints of the clinical trial
The primary endpoint was the occurrence of aGvHD grades
II–IV between randomization and 100 days after HSCT.
Death occurring in patients without aGvHD (grade II or
higher) between randomization and 100 days after HSCT
was considered as treatment failure, equivalent to aGvHD
grade II. The secondary efficacy endpoints were (1) the
severity of aGvHD between time of randomization and
100 days after allo-HSCT, (2) occurrence of aGvHD grades
II–IV, (3) severity of all aGvHD, (4) transplant-related
mortality (NRM), (5) OS, (6) occurrence of leukemic
relapses, and (7) infectious complications.
Safety
The exposure of study treatment was characterized by the
number of administrations and the cumulative dose for both
treatment groups. Adverse events (AEs) were coded using
the Medical Dictionary for Regulatory Activities, version
19.1. Annual Safety Reports were submitted to National
Competent Authority and leading ethic committee as
required by ICH guidelines and national regulations.
Statistical analysis
Primary endpoint of the Pre-GvHD trial was incidence of
aGvHD grades II–IV within 100 days post HSCT. Sample
size calculation was based on previous data [22]. We
expected that aGvHD_MS17-positive samples would pre-
dict 80% probability of developing aGvHD grades II–IV
and a reduction to 41% by preemptive therapy (pilot study,
Supplementary Table 1a; [22]). Seventy-eight patients (2 ×
39) were required to detect a reduction of incidence or
severity of aGvHD grades II–IV or death from 80% in the
placebo group to 50% (odds ratio: 0.3) in the prednisolone
group with a type I error of 5% and a power of 80% using a
two-sided Cochran–Mantel–Haenszel (CMH) test. The
number of patients for randomization was increased to 2 ×
45 to account for dropout. A detailed description of the
statistical plan is provided in the Supplementary materials.
The CMH test and competing risk analysis were used to
compare the two treatment arms for incidence of aGvHD
Fig. 1 Trial flow chart. Patients (N= 267) were enrolled in the PRE-
GVHD trial after informed consent and 259 were eligible. The
screening phase was from day 0 to day +3 and the first samples were
collected and analyzed on day +7 (±3). Upon aGvHD_MS17 CF (CF
> 0.1) positivity, patients were randomized to receive either pre-
dnisolone or placebo for 5 days followed by 19 days of tapering.
Primary endpoint was aGvHD grades II–IV. Without clinical mani-
festation of aGvHD, the medication was be tapered on days 6–19 after
initiation of the therapy. Patients with aGvHD_MS17 negative sam-
ples were continually monitored until either a sample was positive for
the aGvHD_MS17 CF, when they were randomized, or until clinical
manifestation of aGvHD. Upon clinical manifestation of aGvHD, the
patients were treated with standard therapy for aGvHD and counted as
“pattern failure.” Eight patients were excluded due to missing urine
samples and proteomic tests. The observation group consisted of 167
patients. Patients (N= 92; ITT population) were randomized to either
the placebo (N= 48) or prednisolone (N= 44) arms. Fife patients
(N= 3 placebo and N= 2 prednisolone) did not receive the study
medication and were excluded from the safety group (N= 87) and
safety analyses. The per-protocol population (N= 84) excluded
another three patients from the placebo group who either received the
study medication for <3 days (N= 2) or had no positive proteomic
pattern test (N= 1).
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II–IV within 100 days post HSCT. OS in both treatment
arms was compared using Cox proportional hazard models
with left truncation at time of randomization and right
censoring in case of lost to follow-up. Time dependent Cox
models were used to compare OS between all randomized
patients with samples positive for the aGvHD_MS17 test
versus all patients in the observation group with con-
tinuously negative aGvHD_MS17 test results.
Results
Patient characteristics
Between 2009 and 2015, 267 patients were enrolled into
the pre-randomization phase of the Pre-GvHD trial after
the first HSCT; 259 patients were eligible for assessment
of outcome. The disposition of patients and trial flow
diagram are shown in Fig. 1 (Supplementary Table 1).
Urine samples were monitored at indicated time points
and the aGvHD_MS17 CF was calculated by application
of an SVM-based software [21, 23] and considered posi-
tive when the CF was above 0.1 [11, 24]. The mean time
of arrival of the sample at the central laboratory and
transmission of the aGvHD_MS17 CF results for rando-
mization was 30.1 h (95% CI: 29.4–30.8). All patients
were continually monitored until sample positivity when
they were randomized or, in case of negative samples,
until day +80 (±3). Patients were not randomized, if
aGvHD_MS17 CF was negative at the visit, or if exclu-
sion criteria for preemptive treatment were met at time
aGvHD_MS17 CF positivity (Supplementary material).
The follow-up was 1 year after HSCT. Patient character-
istics are summarized in Table 1. The majority of the
patients (70%) were transplanted in complete remission
(CR), received immunosuppressive antibodies (placebo:
75%, prednisolone: 84%, and observation: 78%), were
transplanted from matched unrelated donors using
reduced intensity conditioning regimens (RIC, placebo:
81%, prednisolone: 71%, and observation: 76%), and a
calcineurin-inhibitor-based GvHD prophylaxis (CsA) in
combination with either methotrexate or mycophenolate
mofetil (Table 1). There was a difference in HLA (10
versus 18%) and gender mismatch (12 versus 20%) in the
placebo compared to the prednisolone arm. The obser-
vation group consisted of 167 patients, 65 of those had
samples scoring positive for aGvHD_MS17 CF but were
not randomized for various reasons summarized in
Table 2. Forty-one patients developed aGvHD I–IV (63%)
and four patients (6%) died prior to day 100. Eighteen
patients had positive samples prior to manifestation
(clinical onset) of aGvHD I–IV or death (median: 30 days;
mean: 14 days; range: (7–77), while in 25 patients clinical
manifestation was earlier (median: 6 days, mean: 1 day;
range: −3 to 42). Reasons for no randomization are shown
in Table 2 and Supplementary material exclusion and
inclusion criteria). All patients in the observation group
were treated upon clinical signs of aGvHD with the first-
line standard treatment of aGvHD using corticosteroids
and/or second-line treatment, if necessary, at the discre-
tion of the project leaders in each center.
Randomized study population
The intent-to-treat (ITT) population of the randomized
phase of the Pre-GvHD trial consisted of 92 patients, 44
receiving prednisolone and 48 receiving placebo for 5 days
followed by tapering for 19 days in the absence of clinical
signs of aGvHD. One patient in the placebo group was
randomized by error despite only negative aGvHD_MS17
test results. In the randomized patients, the median time of
aGvHD_MS17 CF sample positivity prior to aGvHD I–IV
manifestation was 25 days (mean: 14 days, range: 7–90), in
randomization to onset aGvHD: 24 days (0–89). Preemptive
therapy was started 2 days after randomization (median 2;
range: 0–6 days) in both groups. The as-per-protocol
population (PP group; N= 84; 42 placebo, 42 pre-
dnisolone arm) excluded patients not receiving the study
drug for at least 3 days. The data generated in the ITT and
the PP groups were similar in all statistical analyses, thus
most analysis shown here are on the ITT population. Rea-
sons for premature withdrawal were withdrawal of consent
(placebo N= 1; prednisolone N= 1; observation N= 3)
and protocol violation (placebo: N= 1). One patient in the
prednisolone group died prior to randomization (Supple-
mentary Table 2). The reasons for early discontinuation of
the study medication in 17 patients (placebo N= 11; pre-
dnisolone N= 6) are summarized in Supplementary
Table 3. Unblinding due to signs of clinical manifest
aGvHD II or higher occurred in 14 patients (placebo N= 9;
prednisolone N= 5).
Outcome of the randomized phase of the PRE-GVHD
trial
The primary endpoint was the incidence of aGvHD II–IV
between randomization and day +100 after HSCT. The
incidence of aGvHD grades II–IV was 25% in the rando-
mized patients. Death during the first 100 days was con-
sidered an event also in patients without aGvHD II–IV.
Figure 2A shows that the cumulative incidence of aGvHD
II–IV, with death as competing event, was similar in the
prednisolone and placebo groups (HR: 1.69, 95% CI:
0.66–4.32, P= 0.27). Table 2 summarizes the incidence
and severity of aGvHD, NRM, and OS in the placebo,
prednisolone (Table 2a), and the observation groups
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(Table 2b). Figure 2B shows the OS in the PP group. The
probability of OS was similar in both arms (HR: 1.06; 95%
CI: 0.52–2.14; P= 0.88; Supplementary Table 4) as it was
in the ITT population. Within 100 days after HSCT, four
patients in the placebo and one patient with aGvHD grade II
in the prednisolone group died, but by day 130 this slight
difference was lost (seven and five deaths, respectively). In
the 1-year follow-up, 15 and 16 patients died, respectively
(Supplementary Table 4). The main causes of death were
relapse (placebo: 6/48; 13%; prednisolone: 5/44; 11%)
followed by NRM (placebo: 4/48; 8%; prednisolone: 4/44;
9%) and other causes (placebo: 4/48; prednisolone: 7/44;
summarized in Supplementary Table 5). The difference in
Table 2 Incidence of aGvHD, NRM, relapse, and OS in all patients:
(a) randomized patients (N= 92); (b) patients in the observation group
(N= 167).














aGvHD grade I 10 38 (17–98)
aGvHD grade II 4 38 (19–53)
aGvHD grades III–IV 4 34 (18–50)
NRM 3 194 (128–315)
Relapse 4 227 (141–332)















aGvHD grade I 11 44 (17–97)
aGvHD grade II 5 39 (17–61)
aGvHD grades III–IV 6 44.3 (17–74)
NRM 9 174 (109–327)
Relapse 5 161 (104–257)
Overall survival 29 66%
(b) Observation group N= 167 (%) Median days
(range)
aGvHD_MS_17 positive 65 (39%)







aGvHD grade I 5 53 (12–110)
aGvHD grade II 4 38 (9–47)
aGvHD grades III–IV 5 34 (13–76)
NRM 3 170 (24–351)
Relapse (death) 0 n.a.
Overall survival 11 61%
GvHD signs prior to
aGvHD_MS17 CF
26






aGvHD grade II 6 25 (13–90)
aGvHD grades III–IV 3 44 (23–74)
NRM 4 146 (88–96)
Relapse (death) 2 418 (351–484)













Renal failure, dialysis 2
Serum disease 1
NRM 5 167 (104–318)
Relapse (death) 3 123 (110–134)
Overall survival 12 60%




aGvHD grade I 29 51 (13–118)
aGvHD grade II 10 38 (18–83)
aGvHD grades III–IV 10 57 (14–92)
NRM 4 111 (39–210)
Relapse 6 231 (111–356)
Overall survival 89 87%
This table summarizes the incidence and severity of acute GvHD
(onset: median days from HSCT to aGvHD), NRM, relapse, and
overall survival in randomized (a) and observation group (b) patients.
Patients in the observation group were subdivided in those with
aGvHD_MS17-CF positive samples (N= 65) and those who had only
negative samples (N= 102). For all groups, all grades of aGvHD
occurring within 130 days and non-relapse mortality (NRM), death
due to relapse, and OS within the 1st year are shown.
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time from HSCT to NRM was not analyzed, due to the low
number of events in both randomized treatment arms.
Patients with only aGvHD_MS17 CF negative test results in
the observation group (N= 102) had a very low risk to die
compared to the randomized patients with aGvHD_MS17
positive samples (N= 91), who had a 2.5-fold (P= 0.002)
increased risk of death within 1 year post HSCT (Fig. 3).
The cumulative incidence of leukemic relapse or progres-
sion (including death due to relapse/progression) at 1 year
after HSCT was slightly higher in the placebo group (20%)
than in the prednisolone group (14%), but the difference
was not statistically significant (P= 0.46). In this analysis,
death unrelated to relapse or progression was considered as
competing risk and patients lost to follow-up were con-
sidered as censored cases (Supplementary Table 6). The
frequency of infections during the screening period prior to
randomization was already higher in the prednisolone group
(23%) than in the placebo group (8%). After the screening
period, infections were reported in 91% of the patients in
the prednisolone group and in 83% of the patients in the
placebo group (Supplementary Table 7). The slightly higher
frequency of infections was observed at all time points
during the study, with the exception of the final visit at 1
year after allo-HSCT.
Safety data
The mean duration of treatment (including taper) was
16 days in the placebo group and 18 days in the pre-
dnisolone group (Supplementary Table 8). The shorter
treatment duration in the placebo arm is explained by the
higher frequency of premature discontinuation of the study
medication in the placebo group (27%) compared to 17% in
the prednisolone group. AEs observed in the two treatment
groups are summarized in Supplementary Table 8. The
frequency of AEs was higher in the placebo when compared
to the prednisolone group (64% and 50%, respectively). The
most common AEs were diarrhea (18% and 10%, respec-
tively), nausea (11 and 5%), vomiting (4 and 5%), and acute
kidney injury (7 against 2%). Serious AEs were more fre-
quent in the placebo group (13 and 7%). The frequency of
(S)AEs attributed to the study medication by the investi-
gators was lower in the placebo (13%) than in the pre-
dnisolone group (21%). AEs leading to withdrawal from
Fig. 2 Outcome of the Pre-GvHD trial. A Cumulative incidence of
acute GvHD (aGvHD) grades II–IV up to day +100 in the ITT
population of randomized patients receiving prednisolone (N= 44,
black solid line) or placebo (N= 48, gray solid line), with death
considered as competing event. Time to aGvHD grade II or higher or
death is left truncated at the time of randomization. aGvHD grade ≥ II
until day +100 occurred in 12 patients of the prednisolone and in eight
of the placebo group. Death by day +100 occurred in one patient in
the prednisolone and four patients in the placebo group. B Overall
survival probability in the prednisolone (N= 44, black solid line) and
placebo (N= 48, gray solid line) ITT population during follow-up of 1
year after HSCT. Overall survival time is left truncated at the time of
randomization.
Fig. 3 Overall survival probability in the randomized versus the
observation group patients. One year OS probability after HSCT is
shown for all randomized (N= 91, black solid line), aGvHD_MS17
pattern positive patients (N= 91; CF > 0.1) and is compared to those
of the observation group patients (N= 102, gray solid line) with only
negative samples for the AGvHD_MS17 CF (CF < 0.1).
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study drug were only observed in the placebo group (five
patients with gastrointestinal complications, one GvHD of
the skin, one patient with insomnia, and one with acute
kidney injury). In addition, one placebo patient died from
pulmonary hemorrhage (Supplementary Table 8).
Discussion
This is the first prospective randomized multicenter trial
using proteomic peptide profiling of patients to assess the
effect of preemptive GvHD-directed therapy post-HSCT.
With sufficient numbers of patients randomized and long
follow-up, the results are disillusioning and reflect the
outcome of previous attempts of preemptive therapy. The
preemptive treatment of imminent aGvHD with 2–2.5 mg
prednisolone/kg BW for 5 consecutive days after rando-
mization did not reduce the clinical development of severe
aGvHD. Other drugs, like etanercept or ruxolitinib, may be
more effective than corticosteroids, but this would have to
be tested in another clinical trial. Several reasons may
account for this negative outcome. The short treatment
period of only 5 days followed by tapering for 19 days
(mean treatment time: 16 days placebo; 18 days pre-
dnisolone; Supplementary Table 3) may not be sufficient to
inhibit the proliferation of allogeneic T cells that induce
aGvHD. Lower overall aGvHD rates in the current trial
could be due to differences in the patient population as
compared to our previous studies [11, 13]. The pilot study
leading to the design of the present trial (Supplementary
Table 9) had more patients with no CR and included mis-
match transplantation. In the Pre-GvHD trial, only good-
risk patients in CR, chronic phase of chronic myeloid leu-
kemia, very good PR, or patients with untreated MDS were
included until 2013. Only when recruitment was still not
completed by 2013, the inclusion criteria were expanded to
include patients transplanted in relapse or refractory patients
with more than 10% leukemic blasts (AML, ALL, and
MDS/MPN). In the previous pilot, the majority of the
patients were transplanted after relapse or treatment failure.
Furthermore, although conditioning regimens did not
influence the data significantly in former analyses,
some RIC protocols are designed to allow for more allo-
geneic reactions. For example, in the previous analyses the
intensive fludarabine–cytosine arabinoside–amsacrine
(FLAMSA) [25] either with TBI or busulfan and ATG
protocol was the most commonly applied RIC, while in the
current trial protocols without particular influence on
immune reactions such as fludarabine/melphalan or fludar-
abine/busulfan made up more than 50% of the RIC proto-
cols (Supplementary Table 11). All these factors together
may explain the lower aGvHD rate in the Pre-GvHD trial
compared to previous studies. Considering safety of
preemptive therapy with prednisolone, neither infections
including virus reactivations (Supplementary Table 7), nor
disease relapses (Supplementary Table 6) differed sig-
nificantly between the prednisolone and the placebo arms.
In addition, the frequency of other AEs was not increased in
the prednisolone group when compared to the placebo
group (Supplementary Table 8). Thus, no specific safety
risk of the preemptive therapy with prednisolone was
identified, although this was a relatively small patient
number to detect rare events.
There was a slight difference in aGvHD development in
the randomized patient groups. As shown in Table 2, the
incidence of aGvHD grades II–IV was slightly higher in the
prednisolone group (N= 11) compared to the placebo group
(N= 8). This may be explained by more HLA-mismatched
donors (N= 5 (10%) placebo; N= 8 (18%) prednisolone)
and higher rate of gender mismatch HSCT in the pre-
dnisolone group (male recipients transplanted from female
donors in the placebo N= 6 (12%); prednisolone N= 9
(20%); Table 1).
We can draw further conclusions from the follow-up of
the patients who entered this large multicenter trial but were
not randomized. aGvHD_MS17 CF positivity predicted
NRM and lower OS within the 1st year after HSCT. Patients
with only aGvHD_MS17 CF negative samples (observation
group; N= 102) had a lower risk for NRM compared to
patients with at least one aGvHD_MS17-positive test (ran-
domized patients; N= 91; HR: 2.49; P= 0.002; Fig. 3).
Preemptive therapy based on laboratory biomarkers was
investigated by Bacigalupo et al. [17], using ATG treatment
in patients after HSCT. They found that the highest risk
group benefitted from this treatment. Later a prospective
randomized trial of prednisolone treatment (1 mg/kg) or
placebo included patients with aGvHD grade I. The outcome
was that aGvHD grade II development was reduced, but
infectious complications were higher and the incidence of
aGvHD III–IV was not reduced [18]. In our trial, the inci-
dence of infectious complications post preemptive pre-
dnisolone treatment was not significantly different to those
in the placebo group. The most promising plasma diagnostic
biomarkers appear to be regenerating islet-derived protein 3
alpha (Reg-3a; [26]), suppression of tumorigenicity 2 (ST2;
[27]), and soluble TNF-receptor 1 (sTNFR1; [28]) as diag-
nostic markers for GvHD and prediction of performance
after HSCT. Reg-3a was tested in samples from 1014 HSCT
patients from three transplantation centers [29]. Recently,
the so-called Ann Arbor Score [15, 28, 30] of aGvHD,
which relies on three biomarkers (Reg-3a, ST2, and
sTNFR1), was implemented in the analysis of patients after
HSCT. It predicts treatment response by day 28 post GvHD
therapy and 6-month NRM irrespective of center-specific
strategies. The international Mount Sinai Acute GvHD
International Consortium has been recently founded and a
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prospective monitoring study for correct diagnosis and NRM
prediction is currently ongoing in an international setting.
Our findings add to the current literature where a cluster of
plasma proteins detected by ELISA were used to predict
outcome after HSCT. Two to six differentially secreted
plasma biomarkers after clinical diagnosis of aGvHD grade
II or higher indicated decreased OS and increased NRM
[14–16]. Prediction of OS and NRM was also studied by
Luft et al. [31], who used an “Endothelial Activation and
Stress Index” (EASIX, an algorithm using lactate dehy-
drogenase (U/L) multiplied by creatinine (mg/dL) and
divided by platelets (109 cells per L)) to predict NRM and
death in patients after HSCT [31, 32]. However, only
aGvHD_MS17 can be used to predict overall aGvHD and/or
to guide preemptive therapy in patients after HSCT without
prior clinical aGvHD diagnosis. In addition, aGvHD_MS17
monitoring has the potential to characterize new biomarkers/
pathways involved in the development of aGvHD and may
be useful to detect new alternative and much needed ther-
apeutic targets for treatment of severe aGvHD. In addition,
combinations with the other biomarkers, like the EASIX
score, used for predicting outcome prior to HSCT [23] may
be used to pre-select high-risk patients for further analysis
with aGvHD_MS17. Application of aGvHD_MS17 mon-
itoring between days +7 and +21 led to a higher predictive
value of aGvHD than at later time points. An early analysis
(e.g., day +14 (±7) post HSCT) using aGvHD_MS17 in the
clinical practice could be helpful to recognize patients at
high risk to develop aGvHD and/or is prone to NRM within
the 1st year after HSCT. In our study, we observed that the
previously established aGvHD_MS17 urine peptide marker
pattern allowed the prediction of 2.5-fold higher NRM.
Thus, a positive aGvHD_MS17 test result by day +14 may
help to guide intensified clinical monitoring of patients with
high risk of developing aGvHD or NRM to administer
effective other immunosuppressive therapy or intensified
care early on.
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